Treatment of Inflammatory Bowel Disease with Biologics (eBook, PDF)
-23%
72,95 €
Statt 94,99 €**
72,95 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar
Versandkostenfrei*
36 °P sammeln
-23%
72,95 €
Statt 94,99 €**
72,95 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar
Versandkostenfrei*

Alle Infos zum eBook verschenken
36 °P sammeln
Als Download kaufen
Statt 94,99 €**
-23%
72,95 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar
36 °P sammeln
Jetzt verschenken
Statt 94,99 €**
-23%
72,95 €
inkl. MwSt.
**Preis der gedruckten Ausgabe (Gebundenes Buch)
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
36 °P sammeln
  • Format: PDF


This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field.
Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists,
…mehr

Produktbeschreibung
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field.

Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

  • Produktdetails
  • Verlag: Springer-Verlag GmbH
  • Seitenzahl: 335
  • Erscheinungstermin: 9. November 2017
  • Englisch
  • ISBN-13: 9783319602769
  • Artikelnr.: 52944441
Autorenporträt
Adam S. Cheifetz, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Joseph D. Feuerstein, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Inhaltsangabe
1. Mechanism of Action and Pharmacokinetics of Biologics
Alan C. Moss
2. Anti-tumor Necrosis Factor Agents in Ulcerative Colitis Kindra Clark-Snustad, Ives Hot, Scott Lee
3. Anti-tumor Necrosis Factor Agents in Crohn's Disease Byron P. Vaughn
4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease Sarah Flier
5. Use of Biologics in the Postoperative Management of Crohn's Disease Benjamin H. Click, Miguel Reguiero
6. Biologics in Pregnancy and Breastfeeding Jill K. J. Gaidos, Sunanda V. Kane
7. Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease Parambir S. Dulai, Corey A. Siegel
8. Therapeutic Drug Monitoring of Biologic Agents Frank I. Scott, Mark T. Osterman
9. Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks Afrin Kamal, Bret Lashner
10. Cessation of Biologics - Can it be Done? Hang Hock Shim, Cynthia H. Seow
11. Biologic Therapy in Pediatric Inflammatory Bowel Disease Sona Patel, Jennifer Strople
12. Infectious Complications of Biologics Renée M. Marchioni Beery, Joshua R. Korzenik
13. Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy Julia Hughes, Millie D. Long
14. Non-infectious and Non-malignant Complications of Biologics Raymond Cross
15. Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances Asher Kornbluth
16. Anti-Integrin Agents in IBD: Efficacy and Risk of Complications Jimmy K. Limdi, Francis A. Farraye
17. Novel Agents in Inflammatory Bowel Disease Fernando Velayos
18. Quality, Safety, and Practical Considerations of Using Biologic Therapies Gil Melmed